Pfizer has officially declared its £69 billion bid to acquire AstraZeneca dead - but hasn't ruled out another attempt in a few months' time. The US company has been in open pursuit of AstraZeneca ...

Pfizer has made a new and improved bid to acquire AstraZeneca with an offer worth £69.3 billion pounds ($116.6 billion) or £55 a share – and says this is its best and final offer for the firm.

In July, AstraZeneca declared a worldwide cessation of its COVID-19 vaccine, Vaxzevria, due to an “excess of updated vaccines.” Earlier, Pfizer raised its 2024 guidance to $8.5 billion from $8 ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

The company is already working with multiple large hospitals in the U.S. and Israel, as well as drug companies, including AstraZeneca and Pfizer. Promise Bio is now emerging from stealth with a ...

Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

AstraZeneca: It boasts a diversified geographical ... The stock has surged 11.5% year to date. Pfizer: It is one of the largest and most successful drugmakers in the field of oncology.

Pfizer's non-COVID product revenues surged 14% operationally last quarter. The oncology business delivered exceptional ...

Pfizer plans to invest $1 billion in China by 2030 to support innovation, diagnostics, and the biotech sector, aligning with ...